ES2425315R1 - Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria - Google Patents

Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria Download PDF

Info

Publication number
ES2425315R1
ES2425315R1 ES201390008A ES201390008A ES2425315R1 ES 2425315 R1 ES2425315 R1 ES 2425315R1 ES 201390008 A ES201390008 A ES 201390008A ES 201390008 A ES201390008 A ES 201390008A ES 2425315 R1 ES2425315 R1 ES 2425315R1
Authority
ES
Spain
Prior art keywords
prepare
condition
pharmaceutical composition
respiratory disease
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES201390008A
Other languages
English (en)
Other versions
ES2425315A2 (es
Inventor
Oleg Iliich Epshtein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899162&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2425315(R1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010130352/15A external-priority patent/RU2528093C2/ru
Priority claimed from RU2011125992/15A external-priority patent/RU2529783C2/ru
Application filed by Individual filed Critical Individual
Publication of ES2425315A2 publication Critical patent/ES2425315A2/es
Publication of ES2425315R1 publication Critical patent/ES2425315R1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria. La presente invención está relacionada con una composición farmacéutica que consta de a) una forma potenciada y activada de un anticuerpo contra la bradiquinina, b) una forma potenciada y activada de un anticuerpo contra la histamina y c) una forma potenciada y activada de un anticuerpo contra la morfina y el uso de dicha composición para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria.
ES201390008A 2010-07-21 2011-07-15 Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria Pending ES2425315R1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
RU2010130352 2010-07-21
RU2010130352/15A RU2528093C2 (ru) 2010-07-21 2010-07-21 Фармацевтическая композиция и способ лечения острых и хронических заболевания дыхательной системы и синдрома кашля
RU2011125992 2011-06-24
RU2011125992/15A RU2529783C2 (ru) 2011-06-24 2011-06-24 Лекарственное средство для лечения патологического синдрома и способ лечения острых и хронических заболеваний дыхательноый системы и синдрома кашля
PCT/IB2011/002346 WO2012010973A2 (en) 2010-07-21 2011-07-15 Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition

Publications (2)

Publication Number Publication Date
ES2425315A2 ES2425315A2 (es) 2013-10-14
ES2425315R1 true ES2425315R1 (es) 2014-09-08

Family

ID=44899162

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201390008A Pending ES2425315R1 (es) 2010-07-21 2011-07-15 Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria

Country Status (21)

Country Link
US (2) US8795657B2 (es)
EP (1) EP2595655A2 (es)
JP (2) JP2013533269A (es)
CN (1) CN103200964A (es)
AR (1) AR082313A1 (es)
AU (1) AU2011281247B2 (es)
BR (1) BR112013001297A2 (es)
CA (1) CA2805978C (es)
CL (1) CL2013000202A1 (es)
DE (1) DE112011102412T5 (es)
EA (1) EA029228B1 (es)
ES (1) ES2425315R1 (es)
FR (1) FR2962909A1 (es)
GB (1) GB2496800B (es)
IT (1) ITTO20110638A1 (es)
MX (1) MX356678B (es)
MY (1) MY158522A (es)
NZ (1) NZ606977A (es)
PE (1) PE20130387A1 (es)
SG (1) SG187579A1 (es)
WO (1) WO2012010973A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
FR2962656A1 (fr) 2010-07-15 2012-01-20 Oleg Iliich Epshtein Procede pour augmenter l'effet d'une forme activee-potentialisee d'un anticorps
JP2013532182A (ja) 2010-07-15 2013-08-15 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び神経変性疾患に関連する疾患又は状態を治療する方法
ITTO20110638A1 (it) * 2010-07-21 2012-01-22 Oleg Iliich Epshtein Composizione farmaceutica di combinazione e metodi per trattare patologie o stati patologici associati a patologie o stati patologici respiratori
EA029998B1 (ru) * 2010-07-21 2018-06-29 Олег Ильич ЭПШТЕЙН Комбинированная фармацевтическая композиция и способ лечения головокружения различного генеза, кинетоза и вегетососудистой дистонии
ITTO20110627A1 (it) * 2010-07-21 2012-01-22 Oleg Iliich Epshtein Composizione farmaceutica di combinazione e metodi per trattare diabete e patologie metaboliche
MX2013000807A (es) 2010-07-21 2013-10-28 Oleg Iliich Epshtein Un metodo para el tratamiento del trastorno de hiperactividad con deficit de atencion.
FR2963563A1 (fr) * 2010-08-06 2012-02-10 Oleg Iliich Epshtein Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter et prevenir les maladies infectieuses
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
DE102020007979A1 (de) 2020-12-29 2022-06-30 Charité Universitätsmedizin Institut für Mikrobiologie und Infektionsimmunologie Zusammensetzung zur Behandlung von lnfektionen mit Coronaviren

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2199344C1 (ru) * 2001-12-07 2003-02-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения синдрома кашля
US20100166762A1 (en) * 2000-06-20 2010-07-01 Oleg Iliich Epshtein Method of treating a pathological syndrome

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
WO1994008619A1 (en) 1992-10-08 1994-04-28 The Kennedy Institute Of Rheumatology Treatment of autoimmune and inflammatory disorders
IT1261849B (it) 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
US5629286A (en) 1994-03-31 1997-05-13 Brewitt; Barbara Homeopathic dilutions of growth factors
IL110035A0 (en) 1994-06-16 1994-10-07 Tapuach Natural Technologies 1 Homeopathic formulations
UA32457C2 (uk) 1996-02-12 2000-12-15 Олєг Ільіч Епштейн Лікарський засіб (варіанти) і спосіб медикаментозного впливу на організм
US5834443A (en) * 1996-05-21 1998-11-10 Masiello; Domenick J. Composition and method for treating herpes simplex
RU2114646C1 (ru) 1996-09-30 1998-07-10 Олег Ильич Эпштейн Способ повышения защитных свойств организма при воздействии внешних физических факторов
RU2103999C1 (ru) 1997-01-31 1998-02-10 Олег Ильич Эпштейн Способ лечения алкоголизма
RU2199244C2 (ru) * 2000-10-05 2003-02-27 Самофалова Лариса Александровна Способ получения пищевой муки масличных семян
RU2191602C1 (ru) 2001-06-01 2002-10-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения аллергических и псевдоаллергических реакций
RU2197266C1 (ru) 2001-06-01 2003-01-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения эрозивных и воспалительных заболеваний желудочно-кишечного тракта
RU2206338C1 (ru) 2001-12-07 2003-06-20 Эпштейн Олег Ильич Способ лечения синдрома кашля
RU2209083C1 (ru) 2001-12-26 2003-07-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения кашля
RU2199345C1 (ru) 2001-12-26 2003-02-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции углеводного и жирового обмена
RU2201255C1 (ru) 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
UA76639C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
CA2518965C (en) 2003-03-14 2018-10-30 Nutrition Research Inc. Homeopathic formulations useful for treating pain and/or inflammmation
RU2253478C1 (ru) 2003-10-01 2005-06-10 Эпштейн Олег Ильич Средство для потенцирования лечебных эффектов - усиления действия лекарственного вещества
EP2395021A1 (en) * 2006-06-06 2011-12-14 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
SG190594A1 (en) * 2008-04-29 2013-06-28 Gunvant Devichand Oswal A homeopathic formulation
SG187035A1 (en) 2010-07-15 2013-02-28 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
JP2013532182A (ja) * 2010-07-15 2013-08-15 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び神経変性疾患に関連する疾患又は状態を治療する方法
BR112013000841A2 (pt) * 2010-07-15 2016-06-07 Oleg Lliich Epshtein composições farmacêuticas, métodos de tratamento da obesidade e distúrbios metabólicos relacionados, de redução da massa corpórea de mamífero, do crescimento da massa corpórea de mamífero, do consumo de comida em mamífero, de trtamento de paciente de adicção de substância psicoativa, de adicção de substância psicoativa e uso de forma ativada-potencializada de anticorpo para receptor de canabinoide humano.
ITTO20110631A1 (it) 2010-07-15 2012-01-16 Oleg Iliich Epshtein Composizione farmaceutica di combinazione e metodi per trattare patologie del sistema genitourinario
ITTO20110627A1 (it) 2010-07-21 2012-01-22 Oleg Iliich Epshtein Composizione farmaceutica di combinazione e metodi per trattare diabete e patologie metaboliche
ITTO20110638A1 (it) * 2010-07-21 2012-01-22 Oleg Iliich Epshtein Composizione farmaceutica di combinazione e metodi per trattare patologie o stati patologici associati a patologie o stati patologici respiratori
EA029998B1 (ru) * 2010-07-21 2018-06-29 Олег Ильич ЭПШТЕЙН Комбинированная фармацевтическая композиция и способ лечения головокружения различного генеза, кинетоза и вегетососудистой дистонии
FR2963563A1 (fr) 2010-08-06 2012-02-10 Oleg Iliich Epshtein Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter et prevenir les maladies infectieuses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100166762A1 (en) * 2000-06-20 2010-07-01 Oleg Iliich Epshtein Method of treating a pathological syndrome
RU2199344C1 (ru) * 2001-12-07 2003-02-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения синдрома кашля

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Epstein O. I. et al. Antitussive activity of Anar. Bulletin of Experimental Biology and Medicine, Supplement 1, 2003, páginas 96-98 (todo el documento) *
Epstein O. I. et al. Ultralow doses of antibodies to inflammatory mediators: antitussive properties of antibodies to bradykinin, histamine and serotonin. Bulletin of Experimental Biology and Medicine, Supplement 1, 2003, páginas 146-149 (todo el documento) *
Jonas W. B. et al. A critical overview of homeopathy. Ann. Intern. Med. 2003, Vol. 138, páginas 393-399 (todo el documento) *
Shang A. et al. Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. The Lancet. 27.08.2005, Vol. 366, páginas 726-732 (todo el documento) *
Vickers A. J. et al. Clinical Trials of Homeopathy and Placebo: Analysis of a Scientific Debate. The Journal of Alternative and Complementary Medicine. 2000, Vol. 6, Nº 1, páginas 49-56 (todo el documento) *

Also Published As

Publication number Publication date
US20150023985A1 (en) 2015-01-22
FR2962909A1 (fr) 2012-01-27
CA2805978C (en) 2016-06-28
SG187579A1 (en) 2013-03-28
CL2013000202A1 (es) 2015-01-16
CN103200964A (zh) 2013-07-10
US8795657B2 (en) 2014-08-05
GB2496800B (en) 2018-05-23
PE20130387A1 (es) 2013-03-30
ES2425315A2 (es) 2013-10-14
JP2013533269A (ja) 2013-08-22
ITTO20110638A1 (it) 2012-01-22
AU2011281247A1 (en) 2013-03-14
CA2805978A1 (en) 2012-01-26
GB2496800A (en) 2013-05-22
BR112013001297A2 (pt) 2017-11-21
MX2013000806A (es) 2013-10-28
AR082313A1 (es) 2012-11-28
JP2016216479A (ja) 2016-12-22
GB201302926D0 (en) 2013-04-03
WO2012010973A2 (en) 2012-01-26
EA201300131A1 (ru) 2013-11-29
EA029228B1 (ru) 2018-02-28
DE112011102412T5 (de) 2013-07-04
MX356678B (es) 2018-06-08
US20120225074A1 (en) 2012-09-06
EP2595655A2 (en) 2013-05-29
MY158522A (en) 2016-10-14
WO2012010973A3 (en) 2012-04-26
AU2011281247B2 (en) 2015-07-30
NZ606977A (en) 2015-08-28

Similar Documents

Publication Publication Date Title
ES2425315R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento sintomático de una enfermedad o afección respiratoria
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
CL2016002132A1 (es) Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo.
GT201200313A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BR112012001297A2 (pt) conector.
CO6280490A2 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
BR112015011112A2 (pt) composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença.
BR112015008759A2 (pt) método para a profilaxia e/ou tratamento de sintomas comportamentais e psicológicos associados com doença neurodegenerativa ou sintomas impulsivos associados com doença mental, agente profilático e/ou terapêutico para sintomas comportamentais e psicológicos associados com doença neurodegenerativa ou sintomas impulsivos associados com doença mental, uso de um composto, composto, e, composição farmacêutica
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
CL2013002033A1 (es) Preparacion oral de desintegracion rapida que comprende granulos que comprenden un medicamento, un agente de desintegracion, un aglutinador, un agente de enmascaramiento y un agente de solubilizacion; metodo de preparacion; su uso para la profilaxis y/o tratamiento de un padecimiento bipolar.
BR112014005407A2 (pt) composto, composição farmacêutico, uso do composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de um paciente infectado com hcv
BRPI0908124A2 (pt) Composto, ativador de glucoquinase, composição farmacêutica, uso de um composto ou sal farmacologicamente aceitavél do mesmo, e, métodos de ativação da glucoquinase, e para tratar e/ou prevenir uma doença
ES2429422R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
CL2014003148A1 (es) Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición.
WO2013003669A3 (en) Compositions, methods of use, and methods of treatment
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
CL2013001564A1 (es) Metodo para tratar sobrepeso u obesidad que comprende administrar naltrexona y bupropion; metodo para incrementar la biodisponibilidad de naltrexona y bupropion en una terapia combinada; uso de naltrexona y bupropion para tratar sobrepeso u obesisdad e incrementar la biodisponibilidad de estos farmacos; composicion farmaceutica.
IL243786A0 (en) A drug that contains a pharmaceutical combination of dolutegravir, emtricitabine and tenofovir
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
IN2014MN02236A (es)
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
ES2415029A8 (es) Composición farmacéutica y uso de un anticuerpo para preparar un medicamento destinado a inhibir la producción o amplificar la eliminación de la proteína P24.

Legal Events

Date Code Title Description
FC2A Grant refused

Effective date: 20170828